Evaluation of the mutagenicity of medroxyprogesterone acetate in vitro and in vivo
Herzog, R.; Leuschner, J.
Arzneimittel-Forschung 45(3): 311-314
1995
ISSN/ISBN: 0004-4172 PMID: 7741792 Document Number: 441030
Medroxyprogesterone acetate (CAS 71-58-9) is used for cyclic hormone substitution during the menopause and in hormone therapy of breast cancer. The text substance was investigated for its mutagenic potential in a series of test systems according to the current EC guidelines. There were no indications for a mutagenic potential of medroxyprogesterone acetate.
Document emailed within 1 workday
Related Documents
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362Leuschner, J.; Leuschner, F. 1991: Evaluation of the mutagenicity of chloral hydrate in vitro and in vivo Arzneimittel-Forschung 41(10): 1101-1103
Zamith, H.P.; Paumgartten, F.J.; Speit, G. 1996: Evaluation of the mutagenicity of the molluscicidal latex of Christ's Crown (Euphorbia milii var. hislopii) in mammalian cells in vitro and in vivo Mutation Research 368(1): 15-20
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Werner, A.; Aichberger, A.; Krebs, D. 1996: Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells? Zentralblatt für Gynakologie 118(11): 616-621
Fotherby, K.; Saxena, B.N.; Shrimanker, K.; Hingorani, V.; Takker, D.; Diczfalusy, E.; Landgren, B.M. 1980: A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate Fertility and Sterility 34(2): 131-139
Africander, D.J.; Storbeck, K.-H.; Hapgood, J.P. 2014: A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A) Journal of Steroid Biochemistry and Molecular Biology 143: 404-415
Cooper, A.J.; Sandhu, S.; Losztyn, S.; Cernovsky, Z. 1992: A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 37(10): 687-693
Mantovani, G.; Macciò, A.; Lai, P.; Massa, E.; Ghiani, M.; Santona, M.C. 1998: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate Seminars in Oncology 25(2 Suppl 6: 45-52
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Tomasicchio, M.; Avenant, C.; Du Toit, A.; Ray, R.M.; Hapgood, J.P. 2013: The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor PLOS one 8(5): E62895
Africander, D.; Louw, R.; Verhoog, N.; Noeth, D.; Hapgood, J.P. 2011: Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract Contraception 84(4): 423-435
Govender, Y.; Avenant, C.; Verhoog, N.J.D.; Ray, R.M.; Grantham, N.J.; Africander, D.; Hapgood, J.P. 2014: The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor Plos one 9(5): E96497
Said, S.; Sadek, W.; Rocca, M.; Koetsawang, S.; Kiriwat, O.; Piya Anant, M.; Dusitsin, N.; Sethavanich, S.A.; Affandi, B.; Hadisaputra, W.; Kazi, A.; Ramos, R.M.; D'arcangues, C.; Belsey, E.M.; Noonan, E.; Olayinka, I.; Pinol, A. 1996: Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception Human Reproduction 11(Suppl 2): 1-13
Adedara, I.A.; Adesanoye, O.A.; Farombi, E.O. 2010: Evaluation of antioxidant properties of Mallotus oppositifolium in in-vitro, in-vivo and ex-vivo model systems African Journal of Medicine and Medical Sciences 39 Suppl: 67-72
Boschitsch, E.; Gitsch, E.; Spona, J. 1983: Therapy of the surgical menopause syndrome with depot medroxyprogesterone acetate and its objective evaluation testing the reaction of the anterior pituitary gland to stimulation with gonadotropin-releasing hormone Wiener Klinische Wochenschrift 95(20): 718-724
Gallaher, E.J.; Loomis, T.A. 1975: Metabolism of ethyl acetate in the rat: hydrolysis of ethyl alcohol in vitro and in vivo Toxicology and Applied Pharmacology 34(2): 309-313
Cromwell, P.; Anyan, W. 1998: Depot medroxyprogesterone acetate galactorrhea Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine 23(2): 61
Roland, M.; Leisten, D.; Kane, R. 1976: Endometriosis therapy with medroxyprogesterone acetate Journal of Reproductive Medicine 17(4): 249-252
Bonhomme, M.G.; Potts, D.M.; Fortney, J.A.; Allen, M.Y. 1991: Safety of depot medroxyprogesterone acetate Lancet 338(8772): 942